港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

维立志博-B

56.200

-1.800-3.10%

成交量：15.45万

成交额：870.62万

市值：111.84亿

市盈率：-27.99

高：58.300

开：57.750

低：55.950

收：58.000

52周最高：83.600

52周最低：51.600

股本：1.99亿

香港流通股本：1.53亿

量比：1.00

换手率：0.10%

股息：- -

股息率：- -

每股收益(LYR):-2.008

净资产收益率：--

总资产收益率：--

市净率：97.51

市盈率(LYR):-27.99

市销率: - -

数据加载中...

总览公司新闻资讯公告

维立志博康小强：顺周期突围，做差异化新药 | 36氪专访

维立志博-B10月16日遭主力抛售401.5万元

维立志博-B10月13日主力净流入146.5万元散户资金抛售

维立志博-B10月09日主力净流出347.3万元散户资金买入

维立志博-B(09887)：2款创新药研究成果将亮相第67届ASH年会

维立志博-B10月06日获主力加仓1435.7万元

维立志博-B10月03日获主力加仓520.2万元

维立志博-B：2025 中期报告

香港交易所

维立志博-B09月25日获主力加仓151.3万元

维立志博-B09月23日主力净流出1078.0万元散户资金买入

维立志博-B09月22日主力净流入453.9万元散户资金抛售

维立志博-B(09887)：LBL-047取得美国FDA的IND批准

维立志博注射用LBL - 024启动Ib/Ⅱ期临床适应症为卵巢癌

维立志博-B09月19日遭主力抛售425.2万元

维立志博-B09月17日主力净流出1026.7万元散户资金买入

维立志博-B09月16日主力净流入2139.8万元散户资金抛售

港股异动 | 维立志博-B(09887)早盘涨超10% 核心产品LBL-024黑色素瘤试验近日完成首例用药

港股异动 | 维立志博-B(09887)午后涨超5% LBL-024黑色素瘤Ib/II期临床首例患者入组

维立志博-B(09887)：LBL-024于奥帕替苏米单抗黑色素瘤Ib/Ⅱ期试验的首例患者成功用药

维立志博：用创新穿越周期

Ofweek光电信息网

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/09887/news?page=3"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"维立志博-B","latestPrice":56.2,"timestamp":1763436715066,"preClose":58,"halted":0,"volume":154501,"delay":0,"floatShares":153000000,"shares":199000000,"eps":-2.008042,"marketStatus":"交易中","change":-1.8,"latestTime":"11-18 11:33:25","open":57.75,"high":58.3,"low":55.95,"amount":8706226,"amplitude":0.040517,"askPrice":56.3,"askSize":2100,"bidPrice":56.15,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.858667,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1763438400000},"marketStatusCode":2,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":58,"openAndCloseTimeList":[[1763429400000,1763438400000],[1763442000000,1763452800000]],"volumeRatio":1.004584,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":153000000,"roa":"--","roe":"--","lyrEps":-2.008042,"volumeRatio":1.004584,"shares":199000000,"dividePrice":0,"high":58.3,"amplitude":0.040517,"preClose":58,"low":55.95,"week52Low":51.6,"pbRate":"97.51","week52High":83.6,"institutionHeld":0,"latestPrice":56.2,"committee":-0.909091,"eps":-2.008042,"divideRate":0,"volume":154501,"delay":0,"ttmEps":-1.858667,"open":57.75,"prevYearClose":35,"prevWeekClose":59,"prevMonthClose":53.7,"prevQuarterClose":69.95,"fiveDayClose":59.35,"twentyDayClose":65,"sixtyDayClose":70},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1762531200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2025-11-14","current":-31.205159,"percent":0.896104,"low":-50.052922,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"high":-34.030535,"avg":-41.326136,"sd":3.17833,"marketCap":11734616200},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200}],"updateTime":1763410600146},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2576001987","title":"维立志博康小强：顺周期突围，做差异化新药 | 36氪专访","url":"https://stock-news.laohu8.com/highlight/detail?id=2576001987","media":"36氪","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576001987?lang=zh_cn&edition=fundamental","pubTime":"2025-10-16 17:18","pubTimestamp":1760606290,"startTime":"0","endTime":"0","summary":"维立志博，是一家肿瘤免疫治疗公司，当前有14款候选药物，其中6款进入临床试验阶段。但临床中，存在大量PD-1抑制剂无效或耐药的患者群体。该癌肿患者基数小、缺乏有效药物，目前已经完成关键临床试验入组，2027年有望成为该适应症的首个获批药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251016171957a6bcc1b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251016171957a6bcc1b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2576701926","title":"维立志博-B10月16日遭主力抛售401.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2576701926","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576701926?lang=zh_cn&edition=fundamental","pubTime":"2025-10-16 16:15","pubTimestamp":1760602516,"startTime":"0","endTime":"0","summary":"10月16日, 维立志博-B股价跌1.12%，报收66.25元，成交金额3129.9万元，换手率0.30%，振幅5.52%，量比0.72。维立志博-B今日主力资金净流出401.5万元，连续3日净流出，上一交易日主力净流出379.5万元。该股近5个交易日下跌8.57%，主力资金累计净流出2125.1万元；近20日主力资金累计净流入1538.0万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251016161551a6bcaa4c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251016161551a6bcaa4c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2575266290","title":"维立志博-B10月13日主力净流入146.5万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2575266290","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575266290?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 16:15","pubTimestamp":1760343354,"startTime":"0","endTime":"0","summary":"10月13日, 维立志博-B股价涨0.72%，报收70.40元，成交金额3674.1万元，换手率0.35%，振幅5.08%，量比0.63。维立志博-B今日主力资金净流入146.5万元，上一交易日主力净流出823.4万元。该股近5个交易日下跌2.96%，主力资金累计净流入2192.6万元；近20日主力资金累计净流入5274.2万元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101316212594c6182d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101316212594c6182d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2574145727","title":"维立志博-B10月09日主力净流出347.3万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2574145727","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574145727?lang=zh_cn&edition=fundamental","pubTime":"2025-10-09 16:15","pubTimestamp":1759997723,"startTime":"0","endTime":"0","summary":"10月09日, 维立志博-B股价跌7.72%，报收72.90元，成交金额5840.8万元，换手率0.51%，振幅8.86%，量比0.79。维立志博-B今日主力资金净流出347.3万元，上一交易日主力净流入1781.2万元。该股近5个交易日上涨4.22%，主力资金累计净流入4095.6万元；近20日主力资金累计净流入5673.6万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510091619479724e0d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510091619479724e0d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2574058859","title":"维立志博-B(09887)：2款创新药研究成果将亮相第67届ASH年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2574058859","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574058859?lang=zh_cn&edition=fundamental","pubTime":"2025-10-09 06:27","pubTimestamp":1759962422,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，美国血液学会(ASH)公布了第67届年会摘要评审结果。公司2款创新药共5篇研究摘要成功入选，包括1篇口头报告、3篇壁报展示和1篇在线发表。公司已连续多年在ASH、美国临床肿瘤学会(ASCO)等国际舞台上发表创新药研发成果。此次多项研究成果集中入选第67届ASH年会，代表了国际学术界对公司科研创新实力的高度认可。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1352838.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ASH","09887","BK1574","BK1161","BK4109","159992","LU2463526074.USD","06978"],"gpt_icon":0},{"id":"2573673128","title":"维立志博-B10月06日获主力加仓1435.7万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2573673128","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573673128?lang=zh_cn&edition=fundamental","pubTime":"2025-10-06 16:15","pubTimestamp":1759738536,"startTime":"0","endTime":"0","summary":"10月06日, 维立志博-B股价涨3.65%，报收75.30元，成交金额5104.8万元，换手率0.45%，振幅4.96%，量比0.91。维立志博-B今日主力资金净流入1435.7万元，上一交易日主力净流入520.2万元。该股近5个交易日上涨19.71%，主力资金累计净流入4430.8万元；近20日主力资金累计净流入4080.8万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025100616180194bc9368&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025100616180194bc9368&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2572750003","title":"维立志博-B10月03日获主力加仓520.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2572750003","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572750003?lang=zh_cn&edition=fundamental","pubTime":"2025-10-03 16:16","pubTimestamp":1759479362,"startTime":"0","endTime":"0","summary":"10月03日, 维立志博-B股价涨0.90%，报收72.65元，成交金额4797.3万元，换手率0.43%，振幅4.38%，量比0.98。维立志博-B今日主力资金净流入520.2万元，连续7日净流入，上一交易日主力净流入705.8万元。该股近5个交易日上涨13.49%，主力资金累计净流入3087.0万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入3243.5万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251003162137971e34cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251003162137971e34cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2570535668","title":"维立志博-B：2025 中期报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2570535668","media":"香港交易所","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570535668?lang=zh_cn&edition=fundamental","pubTime":"2025-09-26 21:49","pubTimestamp":1758894590,"startTime":"0","endTime":"0","summary":"维立志博2025年上半年亏损由去年同期的1.80亿元人民币减少7.8%至1.66亿元。期内研发成本增加56.9%至1.32亿元,主要由于LBL-024生物制品许可申请筹备工作相关的CMC开发里程碑开支增加,以及加快LBL-024及LBL-034的患者入组和临床进展。行政开支减少39%至3,583万元,主要由于2024年上半年授出的股份奖励即时归属并确认相关开支,但部分被2025年上半年产生的上市开支增幅所抵销。截至2025年6月30日,公司现金及现金等价物以及按公允价值计入损益的金融资产合共为4.52亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250927013400a6a09939&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250927013400a6a09939&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161"],"gpt_icon":1},{"id":"2570042691","title":"维立志博-B09月25日获主力加仓151.3万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2570042691","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570042691?lang=zh_cn&edition=fundamental","pubTime":"2025-09-25 16:16","pubTimestamp":1758788172,"startTime":"0","endTime":"0","summary":"09月25日, 维立志博-B股价涨2.07%，报收64.10元，成交金额1661.7万元，换手率0.17%，振幅3.18%，量比0.34。维立志博-B今日主力资金净流入151.3万元，上一交易日主力净流入49.0万元。该股近5个交易日下跌4.19%，主力资金累计净流出849.0万元；近20日主力资金累计净流入2666.8万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250925162942a69d303b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250925162942a69d303b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2569712758","title":"维立志博-B09月23日主力净流出1078.0万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2569712758","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569712758?lang=zh_cn&edition=fundamental","pubTime":"2025-09-23 16:15","pubTimestamp":1758615352,"startTime":"0","endTime":"0","summary":"09月23日, 维立志博-B股价跌7.75%，报收61.90元，成交金额8666.0万元，换手率0.89%，振幅8.94%，量比1.12。维立志博-B今日主力资金净流出1078.0万元，上一交易日主力净流入453.9万元。该股近5个交易日下跌11.11%，主力资金累计净流出2493.8万元；近20日主力资金累计净流入1729.9万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250923163532a7312e48&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250923163532a7312e48&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2569369247","title":"维立志博-B09月22日主力净流入453.9万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2569369247","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569369247?lang=zh_cn&edition=fundamental","pubTime":"2025-09-22 16:15","pubTimestamp":1758528937,"startTime":"0","endTime":"0","summary":"09月22日, 维立志博-B股价涨5.17%，报收67.10元，成交金额3805.1万元，换手率0.38%，振幅6.97%，量比0.48。维立志博-B今日主力资金净流入453.9万元，上一交易日主力净流出425.2万元。该股近5个交易日上涨3.71%，主力资金累计净流入724.1万元；近20日主力资金累计净流入1725.1万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922161900953d6251&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922161900953d6251&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2569206270","title":"维立志博-B(09887)：LBL-047取得美国FDA的IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2569206270","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569206270?lang=zh_cn&edition=fundamental","pubTime":"2025-09-22 12:13","pubTimestamp":1758514401,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，美国食品药品监督管理局(美国FDA)已于2025年9月19日批准其自主研发药物LBL-047的新药临床试验(IND)申请。LBL-047是一种由人源化抗血液树突状细胞抗塬2(BDCA2)抗体及经改造的跨膜激活剂和钙调亲环素配体相互作用分子(TACI)胞外域组成的双特异性融合蛋白。目前全球范围内尚无同时靶向BDCA2及TACI的融合蛋白获批或处于临床阶段，表明LBL-047具有同类第一的潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1347800.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维立志博-B(09887)：LBL-047取得美国FDA的IND批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2569773613","title":"维立志博注射用LBL - 024启动Ib/Ⅱ期临床 适应症为卵巢癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2569773613","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569773613?lang=zh_cn&edition=fundamental","pubTime":"2025-09-22 12:03","pubTimestamp":1758513780,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，南京维立志博生物科技股份有限公司的评价LBL - 024联合紫杉醇注射液治疗铂耐药卵巢癌患者的有效性和安全性的开放、多中心Ib/Ⅱ期临床研究已启动。本次试验Ib期主要目的为评价LBL - 024联合紫杉醇注射液治疗铂耐药卵巢癌患者的安全性和有效性；II期主要目的为评价其有效性。注射用LBL - 024为生物制品，适应症为卵巢癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922130806a43b8df3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922130806a43b8df3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2568925133","title":"维立志博-B09月19日遭主力抛售425.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2568925133","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568925133?lang=zh_cn&edition=fundamental","pubTime":"2025-09-19 16:15","pubTimestamp":1758269746,"startTime":"0","endTime":"0","summary":"09月19日, 维立志博-B股价跌4.63%，报收63.80元，成交金额3423.0万元，换手率0.34%，振幅6.35%，量比0.41。维立志博-B今日主力资金净流出425.2万元，连续3日净流出，上一交易日主力净流出417.8万元。该股近5个交易日下跌2.89%，主力资金累计净流出64.3万元；近20日主力资金累计净流入1198.1万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250919162130979cd578&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250919162130979cd578&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2568459490","title":"维立志博-B09月17日主力净流出1026.7万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2568459490","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568459490?lang=zh_cn&edition=fundamental","pubTime":"2025-09-17 16:16","pubTimestamp":1758096964,"startTime":"0","endTime":"0","summary":"09月17日, 维立志博-B股价跌4.09%，报收66.90元，成交金额1.0亿元，换手率0.99%，振幅8.82%，量比1.49。维立志博-B今日主力资金净流出1026.7万元，上一交易日主力净流入2139.8万元。该股近5个交易日上涨6.71%，主力资金累计净流入983.9万元；近20日主力资金累计净流入547.3万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250917162439a725eea9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250917162439a725eea9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2568454581","title":"维立志博-B09月16日主力净流入2139.8万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2568454581","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568454581?lang=zh_cn&edition=fundamental","pubTime":"2025-09-16 16:15","pubTimestamp":1758010550,"startTime":"0","endTime":"0","summary":"09月16日, 维立志博-B股价涨7.89%，报收69.75元，成交金额2.0亿元，换手率1.84%，振幅13.84%，量比5.66。维立志博-B今日主力资金净流入2139.8万元，上一交易日主力净流出334.5万元。该股近5个交易日上涨9.98%，主力资金累计净流入2010.5万元；近20日主力资金累计净流入1654.2万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091616212195310dd3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091616212195310dd3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2567127395","title":"港股异动 | 维立志博-B(09887)早盘涨超10% 核心产品LBL-024黑色素瘤试验近日完成首例用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2567127395","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567127395?lang=zh_cn&edition=fundamental","pubTime":"2025-09-16 10:24","pubTimestamp":1757989451,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B早盘涨超10%，截至发稿，涨8.04%，报69.85港元，成交额7690.52万港元。据悉，LBL-024为针对肺外神经内分泌癌的全球首款达到注册临床阶段的靶向4-1BB受体的疗法，亦有望成为治疗晚期肺外神经内分泌癌的首款获批药物。公开资料显示，维立志博目前拥有14款候选药物，其中6款已进入临床阶段，包括1款核心产品及3款主要产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1345632.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["YANG","HSCEI","BK4614","BK1161","09887"],"gpt_icon":1},{"id":"2566928051","title":"港股异动 | 维立志博-B(09887)午后涨超5% LBL-024黑色素瘤Ib/II期临床首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2566928051","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566928051?lang=zh_cn&edition=fundamental","pubTime":"2025-09-12 14:17","pubTimestamp":1757657835,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B午后涨超5%，截至发稿，涨4.84%，报65港元，成交额2210.7万港元。消息面上，维立志博午间公告称，自主研发的奥帕替苏米单抗顺利完成一项Ib/Ⅱ期临床研究首例患者入组，该研究将探索奥帕替苏米单抗单药或联合用药治疗一线晚期黑色素瘤。据悉，LBL-024为针对肺外神经内分泌癌的全球首款达到注册临床阶段的靶向4-1BB受体的疗法，亦有望成为治疗晚期肺外神经内分泌癌的首款获批药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1344515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2566947599","title":"维立志博-B(09887)：LBL-024于奥帕替苏米单抗黑色素瘤Ib/Ⅱ期试验的首例患者成功用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2566947599","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566947599?lang=zh_cn&edition=fundamental","pubTime":"2025-09-12 12:21","pubTimestamp":1757650887,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，评价奥帕替苏米单抗(PD-L1/4-1BB双特异性抗体LBL-024)单药或联合其他药剂用于一线治疗晚期黑色素瘤的Ib/Ⅱ期临床试验(NCT07099430)首例患者已成功用药。本次开展的Ib/Ⅱ期、多中心临床试验由福建省肿瘤医院陈誉教授牵头，全国多家医院共同参与。该试验旨在评价奥帕替苏米单抗单药或联合用药治疗晚期黑色素瘤的疗效及安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1344491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维立志博-B(09887)：LBL-024于奥帕替苏米单抗黑色素瘤Ib/Ⅱ期试验的首例患者成功用药","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2565246509","title":"维立志博：用创新穿越周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2565246509","media":"Ofweek光电信息网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565246509?lang=zh_cn&edition=fundamental","pubTime":"2025-09-08 10:24","pubTimestamp":1757298240,"startTime":"0","endTime":"0","summary":"2025年上半年，维立志博在资本市场与临床研发两端均交出了亮眼的成绩单。中信里昂发布研报称偏好维立志博的顶尖抗体药技术，涵盖多个具有占据全球市场实力并有重大突破的创新药技术和分子结构，最新的研发进展和临床数据进一步印证了这个结论。因此，维立志博穿越周期的长期战略落地，背后发人深思。维立志博的科学家们洞察到这一核心痛点，创新性地引入了一个能激活T细胞的激动剂4-1BB。LBL-034代表了维立志博在TCE领域的深度和创新高度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250908105045951bba0f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250908105045951bba0f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":3,"totalSize":151,"code":"91000000","status":"200"}]}}